Vascular Endothelial Dysfunction in Sleep Apnea

Launched by COLUMBIA UNIVERSITY · Mar 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called atorvastatin might help patients with obstructive sleep apnea (OSA). OSA is a condition where a person has trouble breathing during sleep, which can lead to various health issues. The researchers want to find out if taking atorvastatin daily for four weeks can reduce inflammation in the blood vessels of patients who are already using a device called CPAP to help them breathe better at night. They are particularly interested in how this medication affects certain markers in the body that indicate inflammation and clotting risks.

To participate in this trial, you need to be at least 18 years old and newly diagnosed with OSA, meaning you haven’t yet started treatment with CPAP. However, if you have a history of certain health conditions, like heart disease or diabetes, or if you regularly take other medications, you may not be eligible. If you join the study, you'll receive either the atorvastatin or a placebo (a pill that looks the same but has no active medication) for the duration of the trial, and your health will be monitored closely. This study is currently looking for participants, so if you think you might qualify, it could be a great opportunity to contribute to important research in sleep apnea treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged ≥18 years
• • Newly diagnosed with obstructive sleep apnea (OSA) who were never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) ≥5 events/hour of sleep.
• Exclusion Criteria:
• • A history of coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue, smoking within the past 5 years
• • Regular use of any medications